CME/CE - PACE-CME

33-48 of 155

MinuteCE®
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
James Burton, DM, FRCP; Leonie Kraft, MD
1.00 credit 9 episodes
- James Burton, DM, FRCP
- Leonie Kraft, MD
- Lucio Manenti, MD, PhD
- Emilio Sanchez, MD, PhD
1.00 credit 9 episodes
The Patient-Clinician Connection in Managing CKD-aP 
The Patient-Clinician Connection in Managing CKD-aP 
MinuteCE®
The Patient-Clinician Connection in Managing CKD-aP 
James Burton, DM, FRCP; Lucio Manenti, MD, PhD
1.00 program credit
- James Burton, DM, FRCP
- Lucio Manenti, MD, PhD
1.00 program credit
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
CME/CE Broadcast Replay
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
Iacopo Olivotto, MD; Ahmad Masri, MD, MS
0.50 credits
- Iacopo Olivotto, MD
- Ahmad Masri, MD, MS
- Pablo Garcia-Pavia, MD, PhD
- Fabian Knebel, MD, PhD
- Caroline Coats, MD
0.50 credits
Behind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell Therapies
Behind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell Therapies
CME/CE
Behind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell Therapies
Irene Caruso
- Irene Caruso
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
CME/CE Broadcast Replay
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
Prof. Ulrich Laufs; Pam R. Taub, MD, FACC, FASPC
0.50 credits
- Prof. Ulrich Laufs
- Pam R. Taub, MD, FACC, FASPC
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Christie Ballantyne, MD
0.50 credits
New Insights in the Management of HCM: Exploring the Clinical Spectrum
New Insights in the Management of HCM: Exploring the Clinical Spectrum
CME/CE Broadcast Replay
New Insights in the Management of HCM: Exploring the Clinical Spectrum
Milind Y. Desai, MD, MBA; Iacopo Olivotto, MD
0.50 credits
- Milind Y. Desai, MD, MBA
- Iacopo Olivotto, MD
- Elena Arbelo, MD, PhD
0.50 credits
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
CME/CE
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
John McMurray, MD; Scott Solomon, MD
0.25 credits
- John McMurray, MD
- Scott Solomon, MD
0.25 credits
The Critical Interplay: CKD, HF, and HyperkaleAmia
The Critical Interplay: CKD, HF, and HyperkaleAmia
MinuteCE®
The Critical Interplay: CKD, HF, and HyperkaleAmia
James Burton, DM, FRCP; Javed Butler, MD
1.00 program credit
- James Burton, DM, FRCP
- Javed Butler, MD
- Ellie Kelepouris, MD, FACP, FAHA
- Patrick Rossignol, MD, PhD
1.00 program credit
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF 
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF 
MinuteCE®
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF 
Ellie Kelepouris, MD, FACP, FAHA; Patrick Rossignol, MD, PhD
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Patrick Rossignol, MD, PhD
1.00 program credit
Future Directions in Managing Hyperkalemia in CKD and HF
Future Directions in Managing Hyperkalemia in CKD and HF
MinuteCE®
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA; James Burton, DM, FRCP
1.00 program credit
- Javed Butler, MD, MPH, MBA
- James Burton, DM, FRCP
1.00 program credit
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
MinuteCE®
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
James Burton, DM, FRCP; Patrick Rossignol, MD, PhD
1.00 program credit
- James Burton, DM, FRCP
- Patrick Rossignol, MD, PhD
1.00 program credit
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
MinuteCE®
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
James Burton, DM, FRCP; Javed Butler, MD, MPH, MBA
1.00 program credit
- James Burton, DM, FRCP
- Javed Butler, MD, MPH, MBA
1.00 program credit
MinuteCE®
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
James Burton, DM, FRCP; Javed Butler, MD
1.00 credit 9 episodes
- James Burton, DM, FRCP
- Javed Butler, MD
- Ellie Kelepouris, MD, FACP, FAHA
- Patrick Rossignol, MD, PhD
1.00 credit 9 episodes
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
MinuteCE®
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Ellie Kelepouris, MD, FACP, FAHA; Javed Butler, MD, MPH, MBA
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Javed Butler, MD, MPH, MBA
1.00 program credit
Potassium Binders: Safety Comes First!
Potassium Binders: Safety Comes First!
MinuteCE®
Potassium Binders: Safety Comes First!
Ellie Kelepouris, MD, FACP, FAHA; Javed Butler, MD, MPH, MBA
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Javed Butler, MD, MPH, MBA
1.00 program credit
Potassium Binders in Practice: Clinical Trial Evidence
Potassium Binders in Practice: Clinical Trial Evidence
MinuteCE®
Potassium Binders in Practice: Clinical Trial Evidence
Ellie Kelepouris, MD, FACP, FAHA; Patrick Rossignol, MD, PhD
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Patrick Rossignol, MD, PhD
1.00 program credit

3/8